CUPERTINO, CA, OneCell Diagnostics, a genomics-based precision oncology company, announced today that it has raised $16 million in an oversubscribed Series A funding round.
The round was led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. The funding will be used to advance its vision of democratizing precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable. Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will join the OneCell board of directors.
OneCell Diagnostics is a genomics-based precision oncology company, providing comprehensive genomic solutions for better cancer management. OneCell’s proprietary technology leverages a combination of next-generation sequencing in combination with strong bioinformatics, AI / ML, and data-analytics for multi-omics biomarkers.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
By VC News Daily
Source: VC News Daily